OPTOS
LONDON, UK, 15 March 2012 – Optos plc (LSE: OPTS), a leading medical retinal imaging company, today announces it has agreed terms to supply Daytona ultra-widefield retinal imaging devices to Luxottica’s OPSM optometry stores in Australia and New Zealand during 2012.
Over the second half of this year, Optos will deliver to OPSM 160 Daytona devices each on a rental basis. OPSM has exclusivity over the commercial supply of Daytona devices in Australia and New Zealand for a 2 year period. Optos will continue to sell other ultra-widefield imaging products to ophthalmologists and optometrists in Australia and New Zealand together with its other devices which include OCT, treatment laser and visual acuity products. Daytona represents the next generation of Optos ultra-widefield retinal imaging technology, and has been scaled to accommodate smaller office spaces while providing high resolution imaging, and adding new auto-fluorescence capabilities. Weighing only about 25 kg, Daytona’s new, ergonomic body is designed to increase patient comfort, as well as make it easier to correctly position the eye. In addition to the smaller, sleeker design, Daytona features an improved user interface with its intuitive, workflow based software. Daytona also offers “plug-n-play” installation, a modular robust build-design to simplify product support, image review capabilities and electronic image storage options. Daytona was designed to allow the globalisation of the core Optos imaging technology, giving the opportunity to offer the benefits of optomap technology to more eyecare professionals and their patients around the world.
Roy Davis, CEO, commented: “We are delighted to enter into this agreement with the leading optometry chain in Australia and New Zealand which brings the opportunity to move ultra-widefield imaging towards the standard of care for retinal imaging in these countries. This is tremendous validation of our strategy to develop the Daytona device in order to take this sight-saving technology to broader markets. Furthermore, it is clear that our decision to acquire the Opto Global business in Australia and expand the direct salesforce there has opened a strong new territory for Optos. We look forward to shipping our first Daytona devices imminently and to securing more customers in our existing and new markets.”
Chris Beer, Luxottica CEO of Asia Pacific, commented: “OPSM continues to increase the leadership position in Australia and New Zealand by raising the eye care standards in the region. The Daytona digital retinal imaging devices offer a much wider image than has previously been available through fundus cameras, and is a key pillar in helping our optometrists to look deeper into their patients’ eyes to detect eye disease. Early detection, in many cases, means management and prevention of long-term issues. This commitment is the next instalment by OPSM raising the bar in eye care”
About Optos Plc
Optos plc has the vision to be The retina company. We aim to be recognised as a leading provider of devices and solutions to eyecare professionals for improved patient care. Optos' core devices produce ultra widefield, high resolution digital images (optomaps®) of approximately 82% of the retina, something no other device is capable of doing in any one image. Our recent acquisition of OPKO instrumentation brings the group optical coherence tomography (“OCT”) diagnostic devices and optical ultrasound scanners, used in the diagnosis and management of eye disease and conditions.
Optos’ widefield retinal imaging technology, combined with the specific data that can be derived from OCT images, has the potential to offer ophthalmologists and optometrists the most powerful tools for disease diagnosis and management. The optomap images provide enhanced clinical information which facilitates the early detection, management and treatment of disorders and diseases evidenced in the retina such as retinal detachments and tears, glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as hypertension and certain cancers. OCT delivers an image that shows a three dimensional, cross-sectional view of the retina in any particular area, typically in the central pole area of the retina around the optic nerve and macula and is used to detect the presence of and understand the severity of disease, determine treatment approaches and monitor post-treatment effect.
Optos has a range of imaging devices that support different customer segments and patient levels: the P200 and 200Dx devices are concentrated on wellness screening carried out by optometrists and ophthalmologists in primary care; the P200C devices are designed to meet the need for more exacting clinical imaging capabilities and standards in secondary care within the ophthalmology market and at optometric practices that are clinically managing a patient base with advanced ocular disease; and the P200MA and 200Tx devices supports ophthalmologists and retinal specialists in the medical care market. Our expanded product range includes visual acuity, perimetry and treatment laser products
For more information please visit our website www.optos.com.
Enquiries:
Optos plc
Roy Davis, CEO
Christine Soden, CFO
Tel: 01383 843 300 M
FTI Consulting
Ben Atwell / Mo Noonan
Tel: 020 7831 3113